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Abstract
Background: Clinical features, complications and treatments of Gaucher’s disease (GD), a rare autosomal–recessive
disorder due to a confirmed lysosomal enzyme (glucocerebrosidase) deficiency, are described.
Methods: All patients with known GD, living in France, with ≥1 consultations (1980–2010), were included in the
French GD registry, yielding the following 4 groups: the entire cohort, with clinical description; and its subgroups:
patients with ≥1 follow-up visits, to investigate complications; recently followed (2009–2010) patients; and patients
treated during 2009–2010, to examine complications before and during treatment. Data are expressed as medians
(range) for continuous variables and numbers (%) for categorical variables.
Results: Among the 562 registry patients, 265 (49.6%) were females; 454 (85.0%) had type 1, 22 (4.1%) type 2, 37
(6.9%) perinatal–lethal type and 21 (3.9%) type 3. Median ages at first GD symptoms and diagnosis, respectively,
were 15 (0–77) and 22 (0–84) years for all types. The first symptom diagnosing GD was splenomegaly and/or
thrombocytopenia (37.6% and 26.3%, respectively). Bone-marrow aspiration and/or biopsy yielded the diagnosis for
54.7% of the patients, with enzyme deficiency confirming GD for all patients. Birth incidence rate was estimated at
1/50,000 and prevalence at 1/136,000. For the 378 followed patients, median follow-up was 16.2 (0.1–67.6) years.
Major clinical complications were bone events (BE; avascular necrosis, bone infarct or pathological fracture) for 109
patients, splenectomy for 104, and Parkinson’s disease for 14; 38 patients died (neurological complications for 15
type-2 and 3 type-3 patients, GD complications for 11 type-1 and another disease for 9 type-1 patients). Forty-six
had monoclonal gammopathy. Among 283 recently followed patients, 36 were untreated and 247 had been
treated during 2009–2010; 216 patients received treatment in December 2010 (126 with imiglucerase, 45
velaglucerase, 24 taliglucerase, 21 miglustat). BE occurred before (130 in 67 patients) and under treatment (60 in 41
patients) with respective estimated frequencies (95% CI) of first BE at 10 years of 20.3% (14.1%–26.5%) and 19.8%
(13.5%–26.1%).
Conclusion: This registry enabled the epidemiological description of GD in France and showed that BE occur even
during treatment.
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Background
Gauchers disease (GD), a rare autosomalrecessive
disorder with an approximate prevalence of 1/75,000
live births worldwide, is due to the deficiency of a lyso-
somal enzyme (glucocerebrosidase, glucosylceramidase
or glucosidase-β acid (EC 3.2.1.45)) [1] or, more rarely,
its activator (saposin C) [2,3]. GD diagnosis is based on
deficient glucocerebrosidase activity in peripheral leuko-
cytes or cultured skin fibroblasts. Genotyping can some-
times provide prognostic information [4]. This lysosomal
storage disease is characterized by liver and spleen en-
largement, and bone manifestations (Erlenmeyer-flask
deformity, osteoporosis, lytic lesions, pathological and
vertebral compression fractures, bone infarcts and avas-
cular necroses leading to degenerative arthropathy) [1,5].
Based on the neurological signs, 3 clinical phenotypes
are recognized: type 1, the classic form usually defined
by the absence of central nervous system impairment, al-
though an association between type-1 GD and Parkin-
sonism has been described [6]; types 2 and 3, both rare
and severe, have neurological involvement [7]; and the
perinatallethal GD type, with perinatal onset and death
before 3 months of age [8]. GD signs usually appear after
a symptom-free period, except in rare cases of fetal on-
set [9]. Thrombocytopenia and anemia are common, and
several biomarkers (chitotriosidase, ferritin, angiotensin-
converting enzyme [ACE] and tartrate-resistant acid
phosphatase [TRAP]) are elevated during GD evolution
[10-17].
Enzyme-replacement therapy (ERT; alglucerase
[Ceredase©, Genzyme Corporation, available since 1991]
[18], followed by imiglucerase [Cerezyme©, Genzyme
Corporation, available since 1996], velaglucerase [Vpriv©,
Shire, available since 2010] [19], and taliglucerase [Uplyso©,
Pfizer, only authorized for temporary use] [20]), is the
reference treatment. Substrate-reduction therapy (SRT),
namely miglustat (Zavesca©, Actelion, available since
2002) [21], is indicated for moderate GD when ERT is
unsuitable. In June 2009, an acute imiglucerase shortage
occurred because of viral contamination (Vesivirus 2117)
of cell cultures and other production problems [22].
Since then, that ERT has been in short supply, which was
further aggravated in August 2009.
Genzyme Corporation developed an international
registry [23] and several countries, e.g., Spain [24,25],
Brazil [26] or Japan [27], identified GD cohorts and
established exhaustive national registries. While the
international registry conducted many important ancil-
lary studies [28-34], its non-exhaustive cohort did not
address public health issues in terms of incidence, preva-
lence and monitoring of care of GD patients. Since 2004,
France has created referral centers dedicated to the clin-
ical management of rare diseases, and assigned them
several objectives, e.g., improving overall patient clinical
care and professional practices, and collecting epidemio-
logical data. In this context, a Referral Center for Lyso-
somal Diseases (RCLD) was established and a national
GD-patient registry was created, in 2009, as a means to
examine and meet some of those goals.
The main aims of this study were to describe the
epidemiological profile of GD patients in France: GD
demographic, clinical, biological and genetic features;
complications in patients with follow-up (20092010);
and treatments for those with recent (20092010)
follow-up based on data collected since 1980 and avail-
able in the French Gaucher Disease Registry (FGDR).
Patients and methods
Registry design
The FGDR developed and maintains a designated RCLD
since 2009. Its Evaluation of Gaucher-DiseaseTreatment
Committee (EGDTC) is a national scientific committee
to monitor and optimize GD management in France.
The French Data-Protection Commissions (CNIL) ap-
proval of the FGDR required oral or written informed
consent from patients or their parents. Data from pa-
tients who did not consent were not entered. The FGDR
was finally certified in 2009 by the French Institute
for Public Health Surveillance (InVS) and the French
National Institute of Health and Medical Research
(INSERM). All GD patients living in France and having
≥1 consultations (i.e., hospitalization or outpatient con-
sultation with a GD specialist) since 1980 were included.
For all patients, GD was diagnosed by demonstration of
deficient glucocerebrosidase activity in leukocytes [35]
or cultured skin fibroblasts. Exhaustive identification of
cases was achieved through 3 sources. Only 3 diagnostic
laboratories (all included in EGDTC) are accredited in
France and, therefore, identify all patients with an en-
zymatic assay for GD. Based on our Reference Centers
expertise, the French national health insurance (Rare
Disease Committee with EGDTC members) validates
each GD diagnosis and authorizes coverage for its treat-
ment. Once experts have validated the case, they can
ask the treating physician to include the patient in our
registry. The indications for treatment are well estab-
lished to maximize efficacy and avoid unnecessary health
insurance expenditures. Each treating physician con-
tacted allowed access to the medical data entered in the
FGDR, which is certified by InVS and INSERM.
Each patients data were also collected by RCLD physi-
cians or clinical research assistants. The FGDR director
controlled data quality. Dr D. Hamroun developed the
original Internet software for the FGDR, using 4th Di-
mension language from 4D (www.4D.com). Data were
collected retrospectively between 2009 and 2010, and as
of 2011, all data have been recorded prospectively.
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A standardized case-report form was used to collect
the following information: initial data (age at diagnosis,
sex, history related or unrelated to GD, symptoms lead-
ing to diagnosis and first symptoms, first diagnostic
exam, phenotype, genotype and affected family mem-
bers); clinical information during the first consultation,
at diagnosis and throughout follow-up; body mass index
expressed according to the World Health Organization
classification; organomegaly (liver and/or spleen, ultra-
sound measurement of the largest diameter); biological
findings initially and throughout follow-up (hemoglobin
level, platelet count, leukocyte count, chitotriosidase, fer-
ritin, ACE, TRAP, gammaglobulin (with respective nor-
mal values of >12 g/dL, >150×103/mm3, >4 × 103/mm3,
<100 nmol/mL/h, <250 ng/L, <45 IU/L, <7 IU/L and
<13 g/L). Plasma chitotriosidase activity was determined
using the fluorescent substrate 4-methylumbelliferylβ-D-
N,N,N-triacetylchitotriose [10]; ACE, TRAP, ferritin
and other markers were measured in the appropriate
local laboratories. Bone findings (X-rays, magnetic res-
onance imaging and, for some patients, scintigraphy and
dual-energy X-ray absorptiometry) were recorded during
follow-up, with identification of intercurrent events, par-
ticularly bone complications. Bone events (BE) were
defined clinically, using the bone indications for treat-
ment recommended by the French National Health
Authority [36]: avascular necrosis of an epiphysis, bone
infarct, pathological and/or vertebral compression frac-
ture(s). Each BE caused a clinical manifestation and
was confirmed radiologically. Bone pain alone was not
considered a BE without radiological confirmation.
Acute bone pain defined a bone crisis. Bone crisis was
included in BE only when a bone infarct was identified.
Any event, GD-related or not, occurring during follow-
up and monitoring of GD-specific therapy was also
recorded.
Study design
This investigation was undertaken to describe and
analyze clinical, biological, radiological and therapeutic
data recorded in the FGDR for all patients from diagno-
sis until 31 December 2010, the closing date. The local
Institutional Review Board of Northern Paris Hospitals,
ParisDiderot University, APHP (Ethics Committee)
reviewed and approved the research project.
To simplify the description, we defined 4 groups: the
entire cohort and its subgroups. Data from the entire co-
hort of patients entered in the FGDR described, when
available, diagnosis characteristics for these patients, the
GD-incidence rate (defined as total number of cases
diagnosed between 1980 and 2010 divided by the total
French population during the same period), birth inci-
dence rate (defined as the total number of cases diag-
nosed between 1980 and 2010, divided by the total
number of live births during the same period) and
prevalence were estimated for the French population.
For patients with ≥1 follow-up visits in addition to the
initial assessment form, we investigated their GD com-
plications (splenectomy, Parkinsons disease (PD), mono-
clonal gammopathy (MG), BE, first treatment and
deaths). Recently followed patients had consulted in
20092010: a map showing the locations of hospitals
monitoring them was drawn. For patients seen and trea-
ted in 20092010, BE were analyzed, before and under
(ERT and/or SRT (ERT/SRT)). Clinical, biological and
radiological monitoring of these recently treated patients
was also investigated. Specific GD ERT (imiglucerase,
velaglucerase, taliglucerase, miglustat) was studied, par-
ticularly during the period of imiglucerase shortage
(June 2009December 2010). Patients were distin-
guished according to their age on 1 June 2009 (≤15 or
>15 years) for the description of the shortage that began
at that time. That age was chosen because it defines the
limit between adult medicine and pediatrics.
Statistical analyses
All statistical analyses were computed with SAS software
(version 9.2; SAS Institute Inc; Cary, NC). Data are
expressed as medians ((range) or interquartile range
[IQR; Q1;Q3]) for continuous variables and numbers (%)
for categorical variables. Because this was a retrospective
study, some data were missing, particularly at the onset
of follow-up (during the diagnosis phase) or at treatment
onset. Given the demonstrated relatively stable clinical
and laboratory parameters of untreated patients after
GD diagnosis [37], the biological data during the next
2 years changed only minimally and were considered
similar to those at diagnosis. Likewise, data for the pre-
vious 2 years under ERT/SRT were stable compared to
those at treatment onset. Under treatment data were
the last values before the end of therapy or at the closing
date. When ERT/SRT was interrupted for <6 months,
patients were always considered to be on treatment.
Non-parametric tests were used to compare categor-
ical variables (Fishers exact test) across patient sub-
groups. A two-sided p<0.05 was considered significant.
For recently treated patients, time to first BE was esti-
mated with the KaplanMeier method for 2 periods:
diagnosis to treatment onset (before ERT) and first ERT
to closing date (under ERT), with only the first BE oc-
curring during each period being considered. Data were
censored when no BE occurred prior to ERT start for
the first analysis, and until the closing date or treatment
discontinuation for the second. We aimed to study a risk
effect of BE. First, the impact of splenectomy, time to
treatment onset (< or ≥2 years after diagnosis, based on
Mistry et al.s demonstration of lower BE risk after the
latter [38]) or age at diagnosis (≤ or >15 years) on BE
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occurrence was tested using the log-rank test; second a
Cox model was used to derive a predictive model. When
several univariate model covariates were significant, a
multivariate Cox model with backward selection was
used to retain only significant ones. For BE under ERT,
the impact of BE occurrence before treatment was also
tested.
Results
Entire registry cohort
The FGDR contained 562 patients with confirmed GD,
living in France and having ≥1 consultations between
1980 and 2011. Patient characteristics at diagnosis are
reported in Table 1. The male/female ratio was 1.0151
(49.6% female), while median age at first symptoms was
15 (077) years. During the 31 years (19802010), 474
patients were diagnosed in France, with an annual me-
dian of 15 (932) patients. The incidence rate was esti-
mated at 0.26 patients/106 person-years and birth
incidence at 1/50,000. The prevalence was 1/136,000.
The most frequent first symptom leading to diagnosis
(available for 232 patients) was splenomegaly and/or
thrombocytopenia, although others were found, includ-
ing anemia in 14, 14 splenectomies, 10 severe hemor-
rhages, 6 neurological symptoms, 3 avascular necroses, 1
vertebral collapse and 1 bone infarct. Although the most
common diagnostic test yielding the diagnosis was bone-
marrow aspiration, all patients diagnoses were con-
firmed by enzymatic assay. Genotypes were determined
for 261 patients, with 203 having homo- (39 patients) or
heterozygous p.N370S mutations (164 patients, including
41 with p.L444P/p.N370S mutations). Genotype distribu-
tions differed significantly (p<0.0001): L444P/L444P or
L444P/other were found in 14 (6.4%) phenotype-1, 13
(100%) phenotype-2 and 12 (100%) phenotype-3
patients, while the genotypes N370S/L444P, N370S/other
or N370S/N370S were identified in 203 (93.6%) pheno-
type-1, no phenotype-2 and no phenotype-3 patients.
Other mutations found (associated or not with p.N370S
or p.L444P) were: p.R48W, p.C16W, p.G193R, p.K303I,
p.W312S, p.G377S, p.W393R, p.V394L, p.D409H, p.M416I,
p.A446P, p.R463C, p.1416, 1417delAG and p.RecNcil.
Patients were predominantly (84.7%) type 1. Among
161 patients with an affected family member, all but 3
(1 mother, 1 uncle, 1 cousin) were siblings. Ninety-seven
patients died: 37 perinatal deaths (28 fetuses and 9 new-
borns <3 months old) and 60 later (33 type 1, 22 type 2
and 5 type 3).
Followed patients
A total of 378 patients, predominantly type 1, had ≥1
follow-up visits after their initial evaluations. The me-
dian follow-up duration was 16.2 (0.167.6) years. Their
characteristics at diagnosis are reported in Table 1.
During follow-up, 225 complained of chronic bone pain
or clinical bone crisis, 231 had splenomegaly and 163
had hepatomegaly at least once.
Splenectomy
Surgery was performed on 104 patients: 17 before diag-
nosis, 46 at diagnosis and 41 >1 year postdiagnosis.
Among the 41 patients splenectomized after diagnosis,
27 had the surgery before 1991 and only 14 thereafter.
Among the 14 splenectomies after 1991, indications
were: 2 for refractory idiopathic thrombocytopenic
purpura, 2 for splenic rupture, 2 for major hypersplen-
ism, 2 for severe splenic infarct and 2 for splenic
hematoma but 4 had wrong or unknown indications.
Splenectomy was more frequent in type 1 (29.3%) than
type 3 patients (2, 13.3%) (p=0.009). Median age at
splenectomy was 24.6 (376) years. Only 3 patients were
taking ERT/SRT when splenectomy was performed for
splenic complications.
BE
One hundred and nine patients experienced BE during
follow-up, with a median of 1 (18) BE per patient and a
total of 223 BE: 89 avascular necroses, 40 bone infarcts,
67 pathological fractures and 27 vertebral collapses. Sites
were known for 188 BE: 56 avascular necroses affected
the femur, 8 the humerus, 5 the tibia and 7 other bones
(astragal, iliac crest, calcaneus), with 13 unknown sites;
15 bone infarcts involved the femur, 5 the tibia, 5 the
iliac crest and 2 other bones, with 13 sites unknown; 11
pathological fractures concerned the wrists, 9 the ribs, 8
the femur, 8 the humerus and 22 other bones, with 9
localizations unknown. Type-1 patients had 107 (30.7%)
BE, type-3 patients had 2 (13.3%), while type-2 patients
had no BE (p=0.009). Median age at first BE was 34.1
(075.9) years. The first BE occurred in 88 patients with-
out treatment and in 22 under ERT/SRT.
MG
Forty-six patients, all type 1, developed MG during fol-
low-up. Median age at MG diagnosis was 48.2 (24.381)
years. The median GD-diagnosis-to-MG-diagnosis inter-
val was 1.3 (047.5) years. MG was not significantly
more frequent in any given genotype (p=0.37): 1 (4%) p.
N370S/p.N370S, 15 (60%) p.N370S/other, 6 (24%) p.
N370S/p.L444P, 1 (4%) p.L444P/other and 2 (8%) in
other/other; 21 patients with MG had no genotype de-
termination. Comparing the p.L444P allele to the others,
no significant difference was found (p=1). Thirteen pa-
tients were on ERT/SRT when MG was diagnosed (but
no pretreatment immunofixation was available), 23 were
treated thereafter and 10 had never been treated at
closing date, despite MG.
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Table 1 Baseline characteristics of the FGDR cohort, and subgroups with any follow-up, recent follow-up or treatment
Baseline characteristic Entire cohort Followed patients Recently seen patients Recently treated patients
(n=562) (n=378) (n=283) (n=247)
No.* Value No.* Value No.* Value No. Value
Sex, n (%) 562 378 283 247
Female 265 (49.6) 182 (48.1) 144 (50.9) 121 (49)
Male 269 (50.4) 196 (51.9) 139 (49.1) 126 (51)
Fetuses 28
Age, years, median (range) [IQR]
First symptom(s) 238 15 (0–77) [5;30] 227 15 (0–77) [5;30] 182 15 (0–62) [5;30] 162 15 (0–62) [5;29]
Diagnosis (without fetuses) 534 22 (0–83.8)
[5.8;38.9]
378 21.9 (0–80.5)
[6.8;36.2]
283 22.6 (0.2–67.5)
[8.4;35.1]
247 22.1 (0.5–67.5)
[8.7;37.7]
Patients diagnosed before 1991, n (%) 562 261 (46.4) 378 181 (47.9) 283 131 (46.3) 247 122 (49.4)
Patients ≤15 years old at diagnosis, n (%) 562 245 (43.6) 378 147 (38.9) 283 102 (36.0) 247 125 (50.6)
1st symptom-to-diagnosis interval,
years, median (range)
238 1 (0–56) 227 1 (0–56) 182 1 (0–56) 162 1 (0–56)
First symptoms, n (%)† 232 216 169 143
Splenomegaly 163 (70.3) 155 (71.8) 120 (71) 109 (38.9)
Hepatomegaly 51 (22) 46 (21.3) 35 (20.7) 33 (11.8)
Thrombocytopenia 114 (49.1) 107 (49.5) 88 (52.1) 76 (27.1)
Bone crisis 8 (3.4) 8 (3.7) 6 (3.6) 6 (2.1)
Chronic bone pain 16 (6.9) 15 (6.9) 13 (7.7) 13 (4.6)
Other 82 (35.3) 73 (33.8) 53 (31.4) 43 (15.5)
Test diagnosing GD, n (%){ 245 233 189 162
Enzyme assay 61 (24.9) 53 (22.7) 48 (25.4) 36 (22.2)
GBA-gene sequencing 1 (0.4) 1 (0.4) 1 (0.5) 1 (0.6)
Bone-marrow aspiration 118 (48.2) 115 (49.4) 93 (49.2) 83 (51.3)
Bone-marrow biopsy 16 (6.5) 16 (6.9) 13 (6.9) 13 (8)
Bone biopsy 5 (2.0) 5 (2.1) 5 (2.6) 5 (3.1)
Hepatic biopsy 9 (3.7) 8 (3.4) 6 (3.2) 4 (2.5)
Spleen histology 33 (13.5) 33 (14.2) 21 (11.1) 18 (11.1)
Other 2 (0.8) 2 (0.9) 2 (1.1) 2 (1.2)
Type, n (%) 536 378 283 247
1 454 (84.7) 348 (92.0) 274 (96.8) 239 (96.8)
2 61 (11.4) 15 (4) 1 (0.4)
3 21 (3.9) 15 (4) 8 (2.8) 8 (3.2)
Genotype, n (%) 261 229 172 155
p.N370S/p.N370S 39 (15.0) 34 (14.8) 28 (16.3) 24 (15.5)
p.N370S/p.L444P 41 (15.7) 37 (16.2) 31 (18.0) 27 (17.4)
p.L444P/p.L444P 17 (6.5) 11 (4.8) 4 (2.3) 4 (2.6)
p.N370S/other 123 (47.1) 114 (49.8) 86 (50) 77 (49.7)
p.L444P/other 24 (9.2) 17 (7.4) 9 (5.2 ) 9 (5.8)
Other/other 17 (6.5) 16 (7) 14 (8.2) 14 (9)
Affected family, n 562 161 378 130 283 108 247 94
Note that recent refers to 2009–2010, i.e., the last 2 years. GBA glucosidase-β acid.
*No. represents the number of patients with available information.
†Several symptoms for each patient.
{All patients had their definitive diagnoses confirmed by enzymatic assay.
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PD
Neurologist-confirmed PD was diagnosed in 14 pa-
tients, all had type-1 GD; 6 had dementia. Median age
at PD diagnosis was 60.4 (38.277.1) years. The me-
dian age at GD diagnosis of patients who developed
PD was 46.2 (4.470.7) years. PD was significantly more
frequent in patients with the p.L444P/p.N370S mutation
versus others (p<0.0001): PD was diagnosed in 1 (2.9%)
p.N370S/p.N370S patient, 2 (1.7%) p.N370S/other and
5 (13.5%) p.N370S/p.L444P; 6 PD patients had no geno-
type determination. Five patients were on ERT/SRT at
PD diagnosis, 7 were treated thereafter and 2 had never
been treated at closing date, despite PD. Treatment (imi-
glucerase or miglustat) did not have any apparent effect
on PD signs. Two patients received miglustat and both
stopped it after 1 year because of PD progression or
dementia.
Treatments
Among the 378 patients with follow-up, 298 (78.8%)
received treatment. The first ERT was alglucerase for 62
(20.8%) patients, imiglucerase for 224 (75.2%), miglustat
for 7 (2.3%), velaglucerase for 4 (13.4%) and taliglucerase
in 1 (0.3%). The median ERT dose (known for 228
patients) was 120 (30284) IU/kg/month, with 204
patients receiving ≥120 IU/kg/month. Sixty-two patients
were given miglustat during follow-up, with a median
treatment duration of 0.7 (0.16.7) years. Ten patients
had an indwelling catheter and 85 received ≥1 ERT
administrations at home. The median diagnosis-to-first-
treatment interval was 9.1 (061.4) years for all 298
patients, but only 1.4 (016) years for the 145 patients
diagnosed after 1991.
Deaths
Thirty-eight patients died during follow-up: type 2 was
fatal for all 15 patients compared to 20 (5.7%) type 1 or
3 (20%) type 3 (p<0.001). Age at death was known for
28 patients: median of 8.4 (0.383.4) years for all de-
ceased, but 64.5 (38.483.4) years for 13 type-1 pa-
tients, 1 (0.32.2) year for the 13 type-2 patients and
8.4 (7.29.6) years for the 2 type-3 patients. Type-2 and
−3 patients died of neurological impairment, whereas
11 type-1 patients deaths were attributed to: 2 lymph-
omas, 3 PD, 1 myeloma, 1 osteosarcoma, 2 with anemia
or thrombocytopenia complications (1 each with myo-
cardial infarct with anemia or pancytopenia) and 2 had
pulmonary hypertension. Mortality was significantly
more frequent (p<0.0001) for patients whose genotypes
carried the p.L444P mutation; most of them had neu-
rological impairment, as reported above: 1 (2.9%) with
p.N370S/p.N370S, 3 (2.6%) p.N370S/other, 4 (10.8%) p.
N370S/p.L444P, 5 (31.2%) p.L444P/other and 6 (54.5%)
p.L444P/p.L444P; 17 deceased patients had no genotype
determination. Fifteen patients were on ERT/SRT when
they died, while all others had never been treated (in-
cluding all type-2 patients).
Recently followed patients
Among followed patients, 95 had no known data during
20092010. Median time since the last hospital consult-
ation for these patients was 10.7 (2.431.6) years. Thus,
283 patients had consulted during 20092010: 36 had
never been treated and 247 patients had received ERT/
SRT during that period. Their characteristics at diagno-
sis are reported in Table 1.
Hospital locations of followed patients
Figure 1 shows where the hospitals caring for the 283
patients with recent follow-up are located. Ninety-five
patients were followed in Paris, including 73 (76.8%) in
the RCLD. Follow-up was done in an internal medicine
department for 152 (54%) patients, hematology for 65
(23%), pediatrics for 30 (11%) and other departments (7
gastroenterology, 6 neurology, 10 rheumatology, 13
others) for 36.
Patients without treatment
Thirty-six patients had never been treated: median diag-
nosis-to-closing-date interval was 7.8 (0.439.9) years,
for 35 type-1 patients and 1 with type 2; 14 patients had
familial GD (all siblings) and 3 patients, who developed
BE (2 avascular necroses, 1 pathological fracture and 1
vertebral collapse) during follow-up, refused treatment.
Recently seen and treated patients
During 20092010, 247 patients (239 type 1 and 8 type
3) received treatment, with median follow-up at 19.3
(0.266.2) years. Among these recently treated patients,
all 5 type-1 patients died at a median age of 65.8 (56.8
83.4) years. Table 2 provides clinical, biological and bone
data at diagnosis, treatment onset and closing date. Clin-
ical findings, biological values and bone findings tended
to improve under ERT/SRT.
During follow-up, 190 BE (73 avascular necroses, 36
bone infarcts, 58 pathological fractures, 23 vertebral
compressions) occurred in 86 patients, with a median of
1.5 (18) BE/patient. Figure 2 shows KaplanMeier esti-
mates of the time to the first BE for the 247 recently
seen and treated patients, between diagnosis and ERT/
SRT onset (9.2 years of follow-up), and between the lat-
ter and the closing date (7.8 years of follow-up). Treat-
ment at the time of BE was imiglucerase for 56 patients,
alglucerase for 5 and miglustat for 4. The median imi-
glucerase/alglucerase dose when BE occurred in 52
patients was 120 (43.5240) IU/kg/month; 42 patients
had doses ≥120 IU/kg/month. The probabilities (95%
confidence interval [CI]) of BE occurring by 10 years
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before and during treatment were estimated at 20.3%
(14.1%26.1%) and 19.8% (13.5%26.1%), respectively.
Before treatment, 67 patients developed 128 BE: 35
patients with 1 BE, 17 with 2 BE and 15 with ≥3 BE;
whereas under treatment, 41 developed 62 BE: 28
patients with 1 BE, 8 with 2 BE and 5 with ≥3 BE, in-
cluding 22 patients with BE before and under ERT/SRT.
The probabilities (95% CI) of BE occurring by 10 years
before ERT/SRT were 11.5% (3.1%19.8%) versus 24.9%
(16.6%33.2%) for age at diagnosis ≤15 years and >15
years, respectively (p=0.047). No other covariates were
found to influence BE occurrence before ERT/SRT. Dur-
ing treatment, the probabilities (95% CI) of experiencing
BE by 10 years were: 11.8% (5.9%17.6%) and 35.9%
(22.2%49.5%) for patients without or with BE (Figure 3)
before ERT/SRT, respectively, with an HR of 9.8 (5.9
16.3) (p<0.001); 29.1% (16.1%42.1%) versus 14.7%
(8.3%21.1%) with and without splenectomy, respect-
ively, with an HR of 2.1 (1.52.9) (p=0.005); 34.9%
(29.8%40.1%) vs 50.3% (46.1%-54.4%) for age at
diagnosis ≤15 years and >15 years, respectively, with an
HR of 0.7 (0.50.98) (p=0.04); and 22.3% (15.1%29.5%)
versus 8.1% (0%17.5%) for diagnosis-to-treatment inter-
val >2 and ≤2 years, respectively, with an HR of 0.5
(0.30.9) (p=0.01). Age at diagnosis >15 years was not
significantly associated with BE under treatment
(p=0.54). In the multivariate analysis with backward
elimination, BE before treatment was the only significant
risk factor retained.
Table 3 reports ERT/SRT prescribed according to the
supply-shortage dates for the 247 recently treated
patients. The first treatment prescribed was imiglucerase
for 185 patients, alglucerase for 50, miglustat for 7, vela-
glucerase for 4 patients and taliglucerase for 1. The me-
dian diagnosis-to-treatment interval was 9.2 (0.047)
years for all patients, but only 1.5 (0.016) years for
patients diagnosed after 1991. The median treatment
duration was 7.8 (018.3) years. During the supply
shortages (JuneAugust 2009), 106 patients discontin-
ued their treatment, 9 switched to miglustat and 46
Figure 1 Map showing the locations of the hospitals monitoring the 283 patients with recent follow-up (2009–2010).
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Table 2 GD clinical, biological and imaging characteristics at specific times for 247 recently treated (2009–2010)
patients
Characteristic No. At diagnosis No. At ERT/SRT onset No. At closing date
Years since diagnosis, median (range) [IQR] 247 – 247 9.2 (0–47) [1.5;17.7] 247 17.6 (0.1–66.2) [9.3;26.2]
Age, years, median (range) [IQR] 247 22.2 (0.5–67.5) [8.7;34.7] 247 36 (1–79) [20.9;48.2] 247 43.4 (3.2–82.4) [29.9;56.7]
Clinical involvement, n (%)*
Pigmentation 184 10 (5.4) 186 14 (7.5) 167 1 (0.6)
Asthenia 184 84 (45.7) 186 106 (57) 167 44 (26.3)
Abdominal pain 184 29 (15.8) 186 43 (23.1) 167 8 (4.8)
Chronic bone pain 184 70 (38.0) 186 79 (42.5) 167 41 (24.6)
Bone crisis 184 25 (13.6) 186 46 (24.7) 167 12 (7.2)
Bleeding 184 57 (31) 186 58 (31.2) 167 12 (7.2)
Neurological sign 184 7 (3.8) 186 14 (7.5) 167 9 (5.4)
Other 184 11 (6) 186 10 (5.4) 167 42 (25.1)
Body mass index, kg/m2, median (range) 49 16.6 (13.6–28.1) 78 20.3 (13.6–28.1) 53 22.2 (14.6–34.4)
Underweight, n (%) 31 (62.3) 31 (39.7) 7 (13.2)
Normal, n (%) 14 (28.6) 41 (52.6) 35 (66.0)
Overweight/obese, n (%) 4 (8.1) 6 (7.7) 11 (20.8)
Liver and spleen*
Splenectomy, n (%) 247 41 (16.6) 247 63 (25.5) 247 65 (26.3)
Splenomegaly†, n (%) 176 174 (98.9) 129 124 (96.1) 76 42 (55.3)
Splenic US, median (range) of
largest diameter, cm
54 15.8 (10–32) 86 18.9 (10–41) 44 13.6 (8–24)
Hepatomegaly, n (%) 146 116 (79.5) 140 118 (84.3) 90 40 (44.4)
Liver US, (median (range) of
largest diameter, cm
23 15 (8.4–22) 81 17.6 (8.4–37) 34 15 (9–22)
Biological parameter, median (range)†
Hemoglobin (g/dL) 140 11.5 (5.3–18.9) 169 11.7 (5.4–17) 188 13.2 (8–16.4)
Leukocyte (×103/mm3) 126 4.9 (0.6–15.4) 153 4.8 (0.5–24) 102 5.7 (2.1–14.1)
Platelet count (×103/mm3) 161 81 (20–420) 185 80 (18–449) 187 160 (18–553)
Platelets (×103/mm3) without
splenectomy
127 80 (20–246) 137 72 (18–189) 144 139 (18–304)
Chitotriosidase (nmol/mL/h) 43 8,900 (239–47,500) 71 9,000 (360–85,500) 106 992 (19–53,400)
TRAP (IU/L) 5 7.1 (1.1–28) 29 10 (4–38) 24 4.5 (1–18.8)
ACE (IU/L) 17 183 (93–1000) 51 190 (3.4–450) 48 57.5 (12–380)
Ferritin (ng/L) 36 500 (40–5000) 74 621 (63–3,230) 72 337 (40–2,200)
Gammaglobulin (g/L) 14 15.8 (9–28.7) 44 15 (6.6–36) 36 12 (5.4–19.9)
Imaging of bone lesions*, n (%)
Erlenmeyer flask 43 9 (20.9) 61 17 (27.9) 50 4 (8)
Osteopenia 43 6 (14) 61 15 (24.6) 50 4 (8)
Cortical erosion 43 3 (7) 61 3 (4.9) 50 0
Lytic lesion 43 4 (9.3) 61 5 (8.2) 50 5 (10)
Avascular necrosis sequelae 43 6 (14) 61 11 (18.0) 50 4 (8)
Infarct sequelae 43 6 (14) 61 8 (13.1) 50 2 (4)
Fracture sequelae 43 0 61 2 (3.3) 50 1 (2)
Infiltration on MRI 40 31 (77.5) 72 53 (73.6) 80 40 (50)
99mTc-Hyperfixation 31 19 (61.3) 56 42 (75) 41 30 (73.2)
99mTc-Hypofixation 31 5 (16.1) 56 5 (8.9) 41 0
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Table 2 GD clinical, biological and imaging characteristics at specific times for 247 recently treated (2009–2010)
patients (Continued)
Bone densitometry, median (range)
T-score neck 10 −0.6 (−2.1 to 1.1) 27 −1.4 (−4.2 to 1.4) 28 −0.6 (−2.9 to 4.5)
T-score lumbar 8 −1.5 (−2.8 to −0.5) 22 −1.8 (−4.2 to 0.8) 29 −0.9 (−3.0 to 6.2)
Z-score neck 10 −0.8 (−2.1 to 1) 20 −0.8 (−2.1 to 1.9) 26 −0.5 (−2.6 to 4.4)
Z-score lumbar 7 −1.9 (−3 to 0.3) 15 −1.1 (−3.1 to 0.5) 24 −0.1 (−3.0 to 7.1)
US ultrasound, MRI magnetic resonance imaging.
*Data from 31 patients were used at diagnosis and at ERT/SRT onset.
†Splenomegaly in non-splenectomized patients.
Figure 2 Time to the first bone event (BE) in 247 GD patients receiving ERT/SRT. The dashed lines represent the curve’s 95% CI; the
estimated probability of BE occurrence after 10 years is reported on the y-axis. (A) Between diagnosis and first treatment during the first 30 years
of follow-up. (B) Between first treatment and end of treatment or closing date during 15 years of follow-up. No. at risk represents the number of
patients followed at the indicated time; No. with BE represents the number of patients with a BE.
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reduced their imiglucerase doses. Two patients received
a combination of miglustat and imiglucerase, which was
continued during the shortage (counted only under imi-
glucerase in Table 3).
Discussion
To date, no other publication has analyzed the compre-
hensive data entered in the FGDR for 562 patients,
minus 3 who refused to participate and 97 who died,
leaving 465 patients (among 65.8 million inhabitants),
yielding prevalence of 1/140,000 inhabitants in France, a
number that is probably underestimated. Concerning the
entire cohort, although type 1 predominated (85%), types
2 and type 3 represented 4% each, along with 37 (6.9%)
perinatallethal type. Moreover, the type-2 incidence
was the same as that of type 3 but its prevalence was
low because of its associated early mortality. The recent
publication on the exhaustive Spanish registry [26]
reported data similar to ours, with 88.3% type 1, 6.7%
type 2 and 5% type 3. Our birth incidence (1/50,000)
was higher than previously reported for the GD fre-
quency in non-Jewish populations from EU countries
[25,39,40], with a prevalence (1/136,000), close to that of
the Spanish registry (1/149,000) [26].
Bone-marrow aspiration (or biopsy) remained the
most common laboratory test (57%) providing the GD
Figure 3 Impact of BE before treatment on BE occurrence under ERT/SRT for 247 treated GD patients. The solid bold grey line
represents patients without BE before treatment; the solid bold black line represents the times to first BE. Dashed lines represent the 95% CI of
those curves; the estimated probability of BE occurrence after 10 years reported on the y-axis.
Table 3 Numbers of recently treated patients given each therapeutic option during ERT shortages according to date
ERT/SRT 2009/06/01 2009/06/30 2009/08/30 2010/04/01 2010/12/31
Imiglucerase*
>15 years 176 153 71 105 98
≤15 years 32 32 25 27 28
Velaglucerase – – – – 45
Taliglucerase – – – – 24
Miglustat 11 14 20 22 21
Without treatment 28 48 131 93 31
Total 247 247 247 247 247
Note that recent refers to 2009–2010, i.e., the last 2 years.
*Only imiglucerase was prescribed to adults (>15 years) or children (≤15 years).
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diagnosis. It is usually the first-line analysis when
thrombocytopenia is associated (or not) with spleno-
megaly and there is no reason to think of immune
thrombocytopenia purpura. It is not mandatory and
should not be done if the GD diagnosis has been
established by enzymatic assay or is already strongly
suspected (e.g., possible family history). Rarely, bone-
marrow aspiration was considered normal but an-
other sample contained the characteristic GD cells.
Fourteen (3.7%) of our 378 followed patients had PD,
reaching a prevalence comparable to that reported by
Bultron et al. [41]. MG and polyclonal gamma globuline-
mia occur frequently in GD [42-45]. Among the 378 fol-
lowed patients, 46 (12.2%) had MG, a rate within the
previously reported range (1% [42] to 35% [45]), and me-
dian gamma globulinemia at ERT/SRT onset in recently
treated patients was 21.7 g/L. Usually, MG is unaffected
by ERT [43,44]. However, for patients whose MG was
diagnosed under treatment, no pretreatment evaluation
was available, and MG had probably been present at
treatment onset.
Before 1991, splenectomy was the only available treat-
ment but, since then, it should not have been performed
(albeit with exceptions) as a GD treatment. However, it
has been used sometimes as a diagnostic tool when
splenomegaly and thrombocytopenia coexisted, but
should no longer be. Fourteen splenectomies were done
after 1991 and after GD diagnosis, usually for patients
with splenic complications (splenic infarcts, spleen rup-
ture or large fibrous splenomegaly not amenable to
ERT) or a mistaken indication.
BE are the most serious GD complications. They are
usually prevented by ERT/SRT, with substantial attenu-
ation of bone pain, bone crises and bone-mineral density
[46], although the BE decrease is difficult to evaluate
without randomized placebo-controlled trials. In addi-
tion, the definition of BE is not homogeneous across
studies. Apparently, ERT/SRT does not prevent all BE,
as indicated by the estimated respective probabilities of
BE occurring by 10 years before and during treatment of
20.3% and 19.8%. It is likely that patients on ERT/SRT
would probably have had more complications had they
not been treated. Furthermore, we showed that BE be-
fore treatment increased the risk of BE under ERT/SRT
and was the only factor retained in our multivariate ana-
lysis. Note that, as reported by Mistry et al. [38], our
univariate analyses also found splenectomy and treat-
ment >2 years after GD diagnosis to increase that risk,
while sex and age at diagnosis ≤15 years were associated
with increased risk of BE before but not under ERT/
SRT. Thus, BE persist as a problem that is not fully
resolved by treatment. The continuing challenges remain
how to identify patients at risk before and under ERT/
SRT, and then to decide whether or not these patients
would benefit from earlier treatment onset and/or dose
intensification.
In summary, the FGDR strong points are its compre-
hensiveness, independence, accreditation and/or certifi-
cation by the various health authorities and cooperation
generated among the different French centers. This
registry also had to manage the imiglucerase shortage,
when more severe GD and children were accorded pri-
ority treatment. The FGDR also enabled, during that
shortage, nationwide management of the ERT/SRT stock
and selection of those patients most in need of therapy
(velaglucerase and taliglucerase). In France, GD-patient
management is organized so that patients receive treat-
ment near their homes, which improves their quality of
life. Even though monitoring is not centralized, the
FGDR identification and tracking of patients should con-
tribute to improving their specific care management.
Abbreviations
ACE: Angiotensin-converting enzyme; BE: Bone events; CI: Confidence
interval; EGDTC: Evaluation of Gaucher-Disease Treatment Committee;
ERT: Enzyme-replacement therapy; FGDR: French Gaucher Disease Registry;
GD: Gaucher’s disease; HR: Hazard ratio; IQR: Interquartile range;
MG: Monoclonal gammopathy; PD: Parkinson’s disease; RCLD: Referral Center
for Lysosomal Diseases; SRT: Substrate-reduction therapy; TRAP: Tartrate-
resistant acid phosphatase..
Competing interests
Research grants from Genzyme France to University Paris–Diderot to fund
statistical analyses and to AP–HP to finance data acquisition. Research grant
from Shire France to APRIMI (Beaujon Hospital’s association) to finance data
acquisition. C. Serratrice, L. Rossi-Semerano and B. Grosbois, received
consulting fees, speaking fees, and/or honoraria from Genzyme (less than
$10,000). C. Serratrice, D. Heraoui, F. Camou, A. Masseau and B. Grosbois
received consulting fees, speaking fees and/or honoraria from Actelion (less
than $10,000). C. Serratrice, F. Camou and B. Grosbois received consulting
fees, speaking fees, and/or honoraria from Shire (less than $10,000).
Authors’ contributions
JS, FM, MV, NB, OF and BF designed research analyzed and interpreted data.
All authors, except for FM, MV and DH were involved in treating patients
and collecting data. JS had full access to all of the study data and takes
responsibility for their integrity and the accuracy of the data analysis. DH
developed the original software for the FGDR. JS, MV, NB and FM wrote the
draft of the paper, which was then corrected and approved by all authors.
All authors read and approved the final manuscript.
Acknowledgments
The authors wish to thank Janet Jacobson for editorial assistance, the RCLD
secretary, Samira Zebiche, GD patients and their physicians, who contributed
to the FDGR (listed in alphabetic order followed by their city): Agape
Philippe (Saint-Denis), Allanore Yannick (Paris), Amir Abdeslem (Vendôme),
Amsallem Daniel (Besançon), Bauduer Fréderic (Bayonne), Benbouker Lotfi
(Tours), Bergelin-Besacon Anne (Le Mans), Bergère Alain (La Flèche), Bernard
Olivier (Paris), Beyler Constance (Paris), Bismuth Mickael (Montpellier), Boiffard
Olivier (Saintes), Bonnet Brigitte (Le Havre), Bordessoule Dominique
(Limoges), Bouheddou Nadia (Moulins), Bouteiller Gilles (Auch), Brissot Pierre
(Rennes), Brottier-Mancini Elisabeth (La Rochelle), Carreiro Miguel
(Montauban), Cassan-Faux Nelly (Châtellerault), Cathebras Pascal
(Saint-Priest-en-Jarez), Ceccaldi Joël (Libourne), Chabrol Brigitte (Marseille),
Cohen-de Lara André (Paris), Cohen-Valensi Rolande (Martigues), Colnot
Fabrice (Épinal), Constantini Denis (Corbeil–Éssonne), Costello Régis
(Marseille), Dalbies Florence (Brest), Danne Odile (Cergy), Deconinck Éric
(Besançon), Delahaye Florence (Évreux), Delattre Pierre (Cayenne), Delieu
Fabienne (Nice), Demeocq François (Clermont-Ferrand), Denis Jacques (Évry),
Descos Bruno (Nice), Desmurs-Clavel Hélène (Lyon), Diallo Boubacar
Stirnemann et al. Orphanet Journal of Rare Diseases 2012, 7:77 Page 11 of 13
http://www.ojrd.com/content/7/1/77
(Remiremont), Djerad Hama (Nevers), Dobbelaere Dries (Lilles), Dreyfus Marie
(Le Kremlin–Bicêtre), Dupriez Brigitte (Lens), Durieu Isabelle (Lyon),
Edan Christine (Rennes), Fabre Sylvie (Montpellier), Feillet François
(Vandœuvre-les-Nancy), Ferry Régine (Charleville-Mézières), Flodrops Hugues
(Saint-Pierre, La Réunion), Fontaine Bertrand (Paris), Gaches Francis
(Toulouse), Gay Claire (Saint-Étienne), Germain Dominique (Garches), Gil
Helder (Besançon), Granier Françoise (Mantes-la-Jolie), Guérin Jacques
(Arpajon), Guillaumat Cécile (Corbeil–Éssonne), Harle Robert (Marseille),
Herbrecht Raoul (Strasbourg), Hutin Pascal (Quimper), Jarnouen de Villartay
Philippe (Pontoise), Jourdan Éric (Nîmes), Kpati Agbo (Lagny-sur-Marne),
Kuster Alice (Nantes), Lackmy-Port-Lis Marylin (Pointe-à-Pitre), Lamagnère
Jean-Pierre (Tours), Lavigne Christian (Angers), Le Bideau Marc (Saint-Nazaire),
Le Coz Marie-Françoise (Lorient), Le Henaff Catherine (Morlaix), Le Lorier
Bernard (Melun), Le Niger Catherine (Brest), Lefebvre Vincent (Rodez),
Leguy-Seguin Vanessa (Dijon), Lejars Odile (Tours), Lèone Jean (Reims),
Leporrier Michel (Caen), Lescoeur Brigitte (Paris), Lèvy Marc (Nanterre), Lidove
Olivier (Paris), Linassier Claude (Tours), Lioure Bruno (Strasbourg), Macro
Margaret (Caen), Maillot François (Tours), Marie Isabelle (Rouen), Mathieu
Sophie (Paris), Mazodier Karine (Marseille), Morel Pierre (Lens), Navarro Robert
(Montpellier), Ninet Jacques (Lyon), Noël Esther (Strasbourg), Oksenhendler
Éric (Paris), Orzechowski Christine (Bry-sur-Marne), Oudot Caroline (Paris),
Pan-Petesch Brigitte (Brest), Pellegrino Béatrice (Saint-Germain), Perreti
Delphine (Le Kremlin–Bicêtre), Pers Yves-Marie (Montpellier), Plantier Isabelle
(Roubaix), Plouvier Emmanuel (Besançon), Pujazon Marie-Christine (Toulouse),
Quinsat Denis (Antibes), Rhorlich Pierre-Simon (Besançon), Rivera Serge
(Bayonne), Roche Jean (Roanne), Ruivard Marc (Clermont-Ferrand), Savoye
Guillaume (Rouen), Sedel Frédéric (Paris), Simon Anne (Paris), Solary Éric
(Dijon), Steiger Jean-Marie (Bourges), Tchamgoue Serge (Libourne), Themelin
Pascal (Beauvais), Tieule Nathalie (Nice), Trab Albert (Nice), Varet Bruno (Paris),
Vives Laurent (Saint-Gaudens), Zenone Thierry (Valence), Zunic Patricia
(Saint-Pierre). The salaries of a statistician and a clinical research associate
who participated in this study were funded, in part, by a grant from
Genzyme France. Genzyme played no role in designing the study; in
collecting, analyzing and interpreting the data; writing the paper; or the
decision to submit the manuscript for publication. Publication of this article
was not contingent upon approval of the study’s sponsors. The
development of the original software for the French Gaucher Disease
Registry (FGDR) was funded by a grant from the association VML (Vaincre les
Maladies Lysosomales). J. Stirnemann’s work was funded, in part, by a grant
from INSERM (Institut National de la Santé et de la Recherche Médicale).
The FGDR was funded, in part, by INSERM and InVS (Institut national de
Veille Sanitaire).
Author details
1INSERM, UMR 738, Laboratoire de Biostatistiques Hôpital Bichat, Assistance
PubliqueHôpitaux de Paris (AP–HP), Paris, France. 2Univ Paris-Diderot,
Sorbonne Paris Cité, Paris, France, INSERM, UMR, Paris 738, France. 3Referral
Center for Lysosomal Diseases (RCLD), Paris, France. 4Hôpitaux Universitaires
Paris Seine–Saint-Denis, AP–HP Service de Médecine Interne, Hôpital
Jean-Verdier, Université, Paris XIII, Bondy, France. 5Laboratoire de Génétique
Moléculaire CHU Montpellier, Hôpital Arnaud-de-Villeneuve, Montpellier,
France. 6Service de Médecine Interne, Hôpital Beaujon, AP–HP, Clichy, France.
7Service de Pédiatrie et Pédiatrie Rhumatologique, Hôpital de Bicêtre, AP–HP,
National Reference Center for Auto-Inflammatory Diseases, Université de
Paris Sud, Le Kremlin–Bicêtre, France. 8Service d'Hématologie
Biologique–Immunologie, CHU Estaing, Clermont-Ferrand, France. 9Service
d’Hématologie, Hôpital Saint-Vincent-de-Paul, Lille, France. 10Service de
Réanimation Médicale, CHU Saint-André, Bordeaux, France. 11Service de
Médecine Interne, Hôpital Saint-Joseph, Marseille, France. 12Service de
Médecine Interne, Etablissements Nord Sud, Site Hôpital Sud, Rennes, France.
13Service de Médecine Interne, CHU de Nancy, Hôpitaux de Brabois,
Vandoeuvre, France. 14Service de Pédiatrie, Hôpital des Enfants, Toulouse,
France. 15Laboratoire de Génétique, Hôpital Cochin, Paris, France. 16Centre de
Biologie Est, Hospices Civils de Lyon, Bron, France. 17Laboratoire de
Biochimie Métabolique, Institut Fédératif de Biologie, CHU Purpan, Toulouse,
France. 18Service de Médecine Interne, CHU Hôtel-Dieu, Nantes, France.
19Unité Fonctionnelle de Génétique Clinique, Groupe Hospitalier
Pitié–Salpêtrière, AP–HP, Paris, France. 20Service de Neuropédiatrie et
Pathologie du Développement, Hôpital Armand-Trousseau, AP–HP, Université
Pierre-et-Marie-Curie UPMC, Paris, France. 21Département de Neurologie,
Hôpital Pitié–Salpêtrière, AP–HP, Paris, France. 22Centre de Référence des
Maladies Héréditaires du Métabolisme de l’Enfant et de l’Adulte, Hôpital
Jeanne-de-Flandre, Lille, France. 23INSERM U 820, Faculté de Médecine Lyon-
Est Claude-Bernard, Lyon, France. 24Centre de Référence Maladies
Métaboliques de l'Enfant et de Adulte (MaMEA), Hôpital Necker-Enfants
Malades et Université Paris, Descartes, Paris, France. 25Hôpitaux Universitaires
de Genève, Service de Médecine Interne Générale, Rue Gabrielle-Perret-Gentil
4, CH-1211, Genève 14, Suisse.
Received: 15 January 2012 Accepted: 7 October 2012
Published: 9 October 2012
References
1. Brady RO, Kanfer JN, Shapiro D: Metabolism of glucocerebrosides. II.
Evidence of an enzymatic deficiency in Gaucher's disease. Biochem
Biophys Res Commun 1965, 18:221–225.
2. Staretz-Chacham O, Lang TC, LaMarca ME, Krasnewich D, Sidransky E:
Lysosomal storage disorders in the newborn. Pediatrics 2009,
123:1191–1207.
3. Christomanou H, Aignesberger A, Linke RP: Immunochemical
characterization of two activator proteins stimulating enzymic
sphingomyelin degradation in vitro. Absence of one of them in a human
Gaucher disease variant. Biol Chem Hoppe Seyler 1986, 367:879–890.
4. Qi X, Grabowski GA: Molecular and cell biology of acid beta-glucosidase
and prosaposin. Prog Nucleic Acid Res Mol Biol 2001, 66:203–239.
5. Grabowski GA: Recent clinical progress in Gaucher disease. Curr Opin
Pediatr 2005, 17:519–524.
6. Beutler E: Gaucher disease. Arch Intern Med 1999, 159:881–882.
7. Kraoua I, Stirnemann J, Ribeiro MJ, Rouaud T, Verin M, Annic A, Rose C,
Defebvre L, Remenieras L, Schupbach M, et al: Parkinsonism in Gaucher's
disease type 1: ten new cases and a review of the literature. Mov Disord
2009, 24:1524–1530.
8. Mignot C, Doummar D, Maire I, de Villemeur TB: Type 2 Gaucher disease:
15 new cases and review of the literature. Brain Dev 2006, 28:39–48.
9. Eblan MJ, Goker-Alpan O, Sidransky E: Perinatal lethal Gaucher disease: a
distinct phenotype along the neuronopathic continuum. Fetal Pediatr
Pathol 2005, 24:205–222.
10. Mignot C, Gelot A, Bessieres B, Daffos F, Voyer M, Menez F, Fallet Bianco C,
Odent S, Le Duff D, Loget P, et al: Perinatal-lethal Gaucher disease. Am J
Med Genet A 2003, 120:338–344.
11. Hollak CE, van Weely S, van Oers MH, Aerts JM: Marked elevation of
plasma chitotriosidase activity. A novel hallmark of Gaucher disease.
J Clin Invest 1994, 93:1288–1292.
12. Deegan PB, Moran MT, McFarlane I, Schofield JP, Boot RG, Aerts JM, Cox TM:
Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher
disease. Blood Cells Mol Dis 2005, 35:259–267.
13. Lieberman J, Beutler E: Elevation of serum angiotensin-converting
enzyme in Gaucher's disease. N Engl J Med 1976, 294:1442–1444.
14. Zimran A, Kay A, Gelbart T, Garver P, Thurston D, Saven A, Beutler E:
Gaucher disease. Clinical, laboratory, radiologic, and genetic features of
53 patients. Medicine (Baltimore) 1992, 71:337–353.
15. Beutler E: Gaucher disease. Blood Rev 1988, 2:59–70.
16. Morgan MA, Hoffbrand AV, Laulicht M, Luck W, Knowles S: Serum ferritin
concentration in Gaucher's disease. Br Med J (Clin Res Ed) 1983, 286:1864.
17. Tuchman LR, Suna H, Carr JJ: Elevation of serum acid phosphatase in
Gaucher's disease. Journal of Mount Sinai Hospital 1956, 23:227–229.
18. Troy K, Cuttner J, Reilly M, Grabowski G, Desnick R: Tartrate-resistant acid
phosphatase staining of monocytes in Gaucher disease. Am J Hematol
1985, 19:237–244.
19. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC,
Mankin HJ, Murray GJ, Parker RI, Argoff CE, et al: Replacement therapy for
inherited enzyme deficiency – macrophage-targeted glucocerebrosidase
for Gaucher's disease. N Engl J Med 1991, 324:1464–1470.
20. Zimran A, Altarescu G, Philips M, Attias D, Jmoudiak M, Deeb M, Wang N,
Bhirangi K, Cohn GM, Elstein D: Phase 1/2 and extension study of
velaglucerase alfa replacement therapy in adults with type 1 Gaucher
disease: 48-month experience. Blood 2010, 115:4651–4656.
21. Shaaltiel Y, Bartfeld D, Hashmueli S, Baum G, Brill-Almon E, Galili G, Dym O,
Boldin-Adamsky SA, Silman I, Sussman JL, et al: Production of
glucocerebrosidase with terminal mannose glycans for enzyme
Stirnemann et al. Orphanet Journal of Rare Diseases 2012, 7:77 Page 12 of 13
http://www.ojrd.com/content/7/1/77
replacement therapy of Gaucher's disease using a plant cell system.
Plant Biotechnol J 2007, 5:579–590.
22. Aerts JM, Hollak CE, Boot RG, Groener JE, Maas M: Substrate reduction
therapy of glycosphingolipid storage disorders. J Inherit Metab Dis 2006,
29:449–456.
23. Hollak CE, Vom Dahl S, Aerts JM, Belmatoug N, Bembi B, Cohen Y, Collin-
Histed T, Deegan P, van Dussen L, Giraldo P, et al: Force majeure:
therapeutic measures in response to restricted supply of imiglucerase
(Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis 2010,
44:41–47.
24. Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G,
Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ, Zimran A: The Gaucher
registry: demographics and disease characteristics of 1698 patients with
Gaucher disease. Arch Intern Med 2000, 160:2835–2843.
25. Giraldo P, Pocovi M, Perez-Calvo J, Rubio-Felix D, Giralt M: Report of the
Spanish Gaucher's disease registry: clinical and genetic characteristics.
Haematologica 2000, 85:792–799.
26. Giraldo P, Alfonso P, Irun P, Gort L, Chabas A, Vilageliu L, Grinberg D, Sa
Miranda CM, Pocovi M: Mapping the genetic and clinical characteristics of
Gaucher disease in the Iberian Peninsula. Orphanet J Rare Dis 2012, 7:17.
27. Sobreira E, Pires RF, Cizmarik M, Grabowski GA: Phenotypic and genotypic
heterogeneity in Gaucher disease type 1: a comparison between Brazil
and the rest of the world. Mol Genet Metab 2007, 90:81–86.
28. Eto Y, Ida H: Clinical and molecular characteristics of Japanese Gaucher
disease. Neurochem Res 1999, 24:207–211.
29. Mistry PK, Weinreb NJ, Kaplan P, Cole JA, Gwosdow AR, Hangartner T:
Osteopenia in Gaucher disease develops early in life: response to
imiglucerase enzyme therapy in children, adolescents and adults. Blood
Cells Mol Dis 2011, 46:66–72.
30. Rosenbloom B, Balwani M, Bronstein JM, Kolodny E, Sathe S, Gwosdow AR,
Taylor JS, Cole JA, Zimran A, Weinreb NJ: The incidence of parkinsonism in
patients with type 1 gaucher disease: data from the ICGG gaucher
registry. Blood Cells Mol Dis 2011, 46:95–102.
31. Tylki-Szymanska A, Vellodi A, El-Beshlawy A, Cole JA, Kolodny E:
Neuronopathic gaucher disease: demographic and clinical features of
131 patients enrolled in the international collaborative gaucher group
neurological outcomes subregistry. J Inherit Metab Dis 2010, 33:339–346.
32. Weinreb NJ, Deegan P, Kacena KA, Mistry P, Pastores GM, Velentgas P, Vom
Dahl S: Life expectancy in Gaucher disease type 1. Am J Hematol 2008,
83:896–900.
33. Fairley C, Zimran A, Phillips M, Cizmarik M, Yee J, Weinreb N, Packman S:
Phenotypic heterogeneity of N370S homozygotes with type I Gaucher
disease: an analysis of 798 patients from the ICGG Gaucher Registry.
J Inherit Metab Dis 2008, 31:738–744.
34. Weinreb NJ, Taylor J, Cox T, Yee J, Vom Dahl S: A benchmark analysis of
the achievement of therapeutic goals for type 1 Gaucher disease
patients treated with imiglucerase. Am J Hematol 2008, 83:890–895.
35. Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A,
Hangartner TN: Effect of enzyme replacement therapy with imiglucerase
on BMD in type 1 Gaucher disease. J Bone Miner Res 2007, 22:119–126.
36. Daniels LB, Glew RH: Beta-glucosidase assays in the diagnosis of
Gaucher's disease. Clin Chem 1982, 28:569–577.
37. Stirnemann J, Belmatoug N, Vincent C, Fain O, Fantin B, Mentre F: Bone
events and evolution of biologic markers in Gaucher disease before and
during treatment. Arthritis Res Ther 2010, 12:R156.
38. Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ: Timing of
initiation of enzyme replacement therapy after diagnosis of type 1
Gaucher disease: effect on incidence of avascular necrosis. Br J Haematol
2009, 147:561–570.
39. Cox TM, Schofield JP: Gaucher's disease: clinical features and natural
history. Baillieres Clin Haematol 1997, 10:657–689.
40. Lacerda L, Amaral O, Pinto R, Aerts J, Sa Miranda MC: The N370S mutation
in the glucocerebrosidase gene of Portuguese type 1 Gaucher patients:
linkage to the PvuII polymorphism. J Inherit Metab Dis 1994, 17:85–88.
41. Bultron G, Kacena K, Pearson D, Boxer M, Yang R, Sathe S, Pastores G, Mistry
PK: The risk of Parkinson's disease in type 1 Gaucher disease. J Inherit
Metab Dis 2010, 33:167–173.
42. Brautbar A, Elstein D, Pines G, Abrahamov A, Zimran A: Effect of enzyme
replacement therapy on gammopathies in Gaucher disease. Blood Cells
Mol Dis 2004, 32:214–217.
43. Grosbois B, Rose C, Noel E, de Roux Serratrice C, Dobbelaere D, Gressin V,
Cherin P, Hartmann A, Javier RM, Clerson P, et al: Gaucher disease and
monoclonal gammopathy: a report of 17 cases and impact of therapy.
Blood Cells Mol Dis 2009, 43:138–139.
44. De Fost M, Out TA, de Wilde FA, Tjin EP, Pals ST, van Oers MH, Boot RG,
Aerts JF, Maas M, Vom Dahl S, Hollak CE: Immunoglobulin and free light
chain abnormalities in Gaucher disease type I: data from an adult cohort
of 63 patients and review of the literature. Ann Hematol 2008,
87:439–449.
45. Marti GE, Ryan ET, Papadopoulos NM, Filling-Katz M, Barton N, Fleischer TA,
Rick M, Gralnick HR: Polyclonal B-cell lymphocytosis and
hypergammaglobulinemia in patients with Gaucher disease.
Am J Hematol 1988, 29:189–194.
46. Sims KB, Pastores GM, Weinreb NJ, Barranger J, Rosenbloom BE, Packman S,
Kaplan P, Mankin H, Xavier R, Angell J, et al: Improvement of bone disease
by imiglucerase (Cerezyme) therapy in patients with skeletal
manifestations of type 1 Gaucher disease: results of a 48-month
longitudinal cohort study. Clin Genet 2008, 73:430–440.
doi:10.1186/1750-1172-7-77
Cite this article as: Stirnemann et al.: The French Gaucher’s disease
registry: clinical characteristics, complications and treatment of 562
patients. Orphanet Journal of Rare Diseases 2012 7:77.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Stirnemann et al. Orphanet Journal of Rare Diseases 2012, 7:77 Page 13 of 13
http://www.ojrd.com/content/7/1/77
